power point presentation on diabetes mellitus

This comprehensive  slide deck of ADA's 2023 Standards of Care contains content created, reviewed, and approved by the American Diabetes Association.  You are free to use the slides in presentations without further permission as long as the slide content is not altered in any way and appropriate attribution is made to the American Diabetes Association (the Association name and logo on the slides constitutes appropriate attribution).

Permission is required from the Association for any commercial use or for reproduction in any print materials (contact [email protected] ).

Using the links to the slide deck will download the deck. You may need to check the folder for downloaded documents on your device to see/open the file. 

Home PowerPoint Templates Template Backgrounds Diabetes PowerPoint Template

Diabetes PowerPoint Template

The Diabetes PowerPoint Template is a special presentation theme for medical professionals. The individuals who are directly and indirectly involve in treatment of diabetes can use this template. This PowerPoint can assist users in demonstrating symptoms, causes, medical issues, and trends for the disease. This template provides a wide range of shapes, clipart icons, and infographics relevant to diabetes topics. These include label diagrams, comparison tables, timeline scale, dashboard, and statistical analysis. Further, individual working in a medical field as doctors, research scientists, pharmacists etc. often present healthcare related topics in public. because the use of graphical content assists users to elaborate their discoveries about diabetes.

The Diabetes PowerPoint Template has 13 slides of high-quality vector graphics. This is a presentation tool to discuss diabetes and related topics in ways that are most appealing to the audience. Such as shapes and graphics demonstrating a body diagram, test device, and data charts. Furthermore, the diabetes PowerPoint presentation is a structured set of slides for medical details of a term or disease. The sequence is as follow:

• 10 early signs of diabetes – Human silhouette label diagram
• Causes – 6 segment infographic bullet list format
• Types of diabetes – 3 comparison tables
• Risk and further complications – Label diagram
• Diabetes prevention – Horizontal hierarchy structure
• Smart food swap can help prevent type 2 diabetes – graphic comparison table
• Diabetes blood test – Two content clipart and text segments slide
• Text collage health and diabetes terms
• TRACK – Bullet list design of diabetes control options
• Diabetes infographics – dashboard style quick facts slide
• lastly, Worldwide statistics of diabetes – data driven area chart and map

This is an editable PowerPoint medical design to effectively convey the useful information. The users can change color theme or image background of diabetes PowerPoint. Moreover, replace it with their company, hospital or business patterns.

Alternatively, you can download the Diabetes presentation template with additional diabetes slides, and compatible with PowerPoint & Google Slides presentations.

You must be logged in to download this file.

Favorite Add to Collection

Details (13 slides)

Supported Versions:

Subscribe today and get immediate access to download our PowerPoint templates.

Related PowerPoint Templates

5-Level Swiss Cheese Model PowerPoint Template

Incident Report PowerPoint Template

Neuroscience PowerPoint Template

Scientific Method Diagram PowerPoint Template

Home Collections Medical Diabetes

Free Diabetes Presentation Templates

Struggling with boring diabetes presentations download free diabetes powerpoint templates and google slides themes that are easy to use and understand. bright colors, creative visuals, and helpful infographics - make your message clear spread awareness about diabetes mellitus, including causes, symptoms, diets, etc. the best choice for doctors.

• Diverse themes: Explore slides dedicated to diabetic ketoacidosis, case studies, diet plans, and even captivating backgrounds for your chosen topic.
• World Diabetes Day: Celebrate this special day with slides that everyone will understand! It will help you raise awareness and make people want to learn more about keeping their sugar in check.
• Let creativity flow: Infographics, multicolor palettes, and a variety of layouts give your presentation a unique and impactful edge.
• Customization: All slides are 100% editable, allowing you to tailor them to your specific needs and add your own touch.
• Multiple formats: Choose from 4:3 or 16:9 aspect ratios, portrait or landscape orientations, and find slides that work seamlessly with any presentation platform.
• Free options to explore: A collection of diabetes PPT presentation free downloads available to let you experience the quality before investing further.
• Doctors, nurses, and teachers: Explain things clearly to patients, friends, and everyone else.
• People who spread the word about diabetes: Teach people how to stay healthy and avoid problems with sugar.
• People living with diabetes: Share your story and help others, or fight for better care with powerful pictures. It will help to share your experiences and make a difference!
• Conferences and workshops: Deliver impactful presentations at medical gatherings, community events, and educational seminars.
• Patient education sessions: Use clear visuals to explain complex topics to patients and families in an accessible and engaging way.
• Awareness campaigns: Create presentations that raise awareness about diabetes , its impact, and steps for prevention and management.
• Online presentations and webinars: Share your knowledge with a wider audience through online platforms using visually compelling slides.

We're here to help you!

What types of diabetes presentation templates are available.

We offer a variety of templates for different topics, including awareness campaigns, patient education, research presentations, and more.

Do I have to be good at design to use these templates?

Not at all! Our templates are made for everyone, even if you're just starting. Just put in your content and change the look with a few clicks – it's that easy!

Are the templates free to download?

Yes, we offer a collection of free slides to download and use.

Can I edit the templates after downloading them?

Yes, you can fully customize the templates with your own content, images, and colors. You can edit them from PowerPoint or Google Slides.

Can I use these templates for commercial purposes?

Yes, you can use our templates for personal and commercial use.

Can I share your templates with others?

Yes, you can share our templates with your friends, colleagues, and anyone else who needs to create a diabetes presentation.

How can I get help if I have trouble using the templates?

We're happy to help! Contact our 24/7 customer support team.

Do you offer any premium diabetes presentation templates?

Yes, we also offer a selection of premium templates.

Diabetes Mellitus

Oct 15, 2014

370 likes | 1.12k Views

Diabetes Mellitus. Prof Seamus Sreenan Dept of Diabetes and Endocrinology, Connolly Hospital, Blanchardstown Mini Med School November 30 th , 2011. Learning Objectives. At the end of this talk you should understand: What diabetes mellitus means

Share Presentation

• diabetes mellitus
• blood glucose levels
• type 2 diabetes mellitus

Presentation Transcript

Diabetes Mellitus Prof Seamus Sreenan Dept of Diabetes and Endocrinology, Connolly Hospital, Blanchardstown Mini Med School November 30th, 2011

Learning Objectives • At the end of this talk you should understand: • What diabetes mellitus means • The difference between types-1 and -2 diabetes • How the different types are treated • The reasons for the current epidemic of diabetes and how it can be prevented • What the complications of diabetes are and how they can be prevented

What is Diabetes? Diabetes Mellitus (sugar diabetes) is a disease characterized by high levels of sugar (glucose) in the blood Fasting glucose ≥ 7.0 (mmol/L)

Blood sugar and health Sugar (glucose) is an important source of energy Insulin is produced by the pancreas when blood sugar is high What is eaten is absorbed into the blood Insulin keeps blood sugar level within the normal range for health

Islet of Langerhans: Pancreas contains insulin-making cells in “islets” Insulinb-cells

Diabetes in a ‘nutshell’ • Insufficient insulin to meet the body’s needs • Either a complete lack (type 1) or relative lack (type 2) • Results in raised blood glucose levels • Untreated diabetes results in short-term symptoms and serious long-term complications • Treatment aims to keep blood glucose levels as close to the normal range as safely possible

Complications of Diabetes • Short term: • Symptoms of diabetes • Dehydration • Diabetic Coma • Infections • Long term: • Kidney • Eye • Heart • Circulation • Amputation

Symptoms of Diabetes People with diabetes often have typical complaints (symptoms): • Thirst and frequent drinking • More frequent urination, particularly at night • Unexplained weight loss • Fatigue • Blurred vision • Frequent infections : skin, genital

Case 1 • JN • 32 year old male • Referred to Emergency Dept by GP • Complaining of thirst, excessive urination, half stone weight loss in the last 6 weeks • No relevant past history • First cousin has diabetes on insulin • On no regular medications • Thin man • Blood sugar level = 24.7 mmol/L

What type of diabetes does JN have? There are 2 main types of diabetes: • Type 1 (15%): Due to total lack of insulin – insulin treatment is required for life • Type 2 (85%): Plenty of insulin which does not work very well in the body. Insulin treatment may be required at some stage but is not required in all patients

Type 1 Young age Normal BMI, not obese No immediate family history Short duration of symptoms (weeks) Can present with diabetic coma (diabetic ketoacidosis) Insulin required Type 2 Middle aged, elderly Usually overweight/obese Family history usual Symptoms may be present for months/years Do not present with diabetic coma Insulin not necessarily required Previous diabetes in pregnancy Differences between type-1 and type-2 Diabetes Mellitus These differences are not absolute

JN • Young age • Thin • No immediate family history • Short duration of symptoms • Insulin treatment required All point to probable type-1 diabetes

The Miracle of Insulin February 15, 1923 Patient J.L., December 15, 1922

Treatment of Type-1 Diabetes Mellitus: Insulin must be administered into the subcutaneous pocket between fat & muscle & avoid injection into fat or muscle. Can be administered by needle and syringe or by pen device

Alternative way to deliver insulin treatment: Continuous insulin infusion (insulin pump)

Islet replacement treatment • Aim to replace the need for insulin treatment • (Kidney) Pancreas transplantation • Islet transplantation – not available in Ireland • Anti-rejection drugs required • Stem cell transplantation - experimental

Case 2 • Ms AJ, a 45 year old woman is concerned she may have diabetes • She had diabetes during her last pregnancy managed with diet • Lately she has been feeling tired but otherwise has no complaints • Her mother and one of her two sisters already have diabetes treated with tablets • She has been overweight since her last pregnancy and has taken a tablet for blood pressure for the last 2 years • She is obese, body mass index 34.5 • Blood pressure is 140/90 but otherwise her examination is normal • She undergoes a testing and her fasting glucose is 9.4 mmol/L • Obese, strong family history, aged in 40s, previous history of diabetes in pregnancy all point to type-2 diabetes

Normal Prediabetes Type 2 diabetes Natural History of Type 2 Diabetes Insulin resistance Increasing insulinresistance Insulin secretion Hyperinsulinemia, then islet cell failure After meal glucose Abnormal glucose tolerance Fasting glucose High sugar levels Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota.

Treatment of Type-2 Diabetes Diet/exercise Oralmonotherapy Oral combination Oral +/- insulin Insulin Diet and exercise my control condition for some time Variety of tablets available when diet exercise no longer work Tablets can be used in combination with each other or with insulin Insulin can also be used alone

Prevalence of Diabetes • Diabetes is very common • It is becoming more common (particularly type-2) • It affects about 200,000 Irish people • 10% of the health budget spent on diabetes

Reason for increasing prevalence of type-2 diabetes The disease is reaching epidemic proportions because: • Rates of overweight/obesity have increased • We have become a physically inactive species • Our diets are increasingly unhealthy

Overweight and obesity are diagnosed by measuring weight and height (Body Mass Index (BMI)): Weight in Kg Height in metres2 Normal = 20-25 Overweight = 25-30 Obese = more than 30 Everyone should know their BMI! BMI =

Can Diabetes be Prevented? To be able to prevent a disease we need to be able to indentify people at particular risk of developing it

Risk factors for type 2 diabetes Certain people are more at risk of diabetes: • Those who are overweight/obese • People with a family history of diabetes • Women who had diabetes during pregnancy or have had a baby weighing more than 9lbs • Physically inactive people • Certain ethnic groups (african, american indian, asian) • People who have high blood pressure or high cholesterol • Age more than 45 years

Can Diabetes be Prevented? Risk of Type 2 Diabetes can be reduced: • Losing weight • Taking regular exercise : walking for 30 mins per day • Eating healthier food:  Less fat (burgers, fries, crisps, sweet foods)  More fibre (fruit and vegetables, wholegrain alternatives for rice, bread) • Cutting down on alcohol consumption Ultimate aim is to reduce the longterm complications

Can the longterm complications be prevented? • Type-1 • 1993: Study showed for the first time that good sugar control can prevent long term complications affecting eyes/kidneys/nerves • Type-2 • 1998: Similar study showed same conclusion for type-2 • Important therefore to know that sugar control is good and monitor frequently

Diabetes Mellitus: Self Monitoring SMBG Patients can draw blood frequently to monitor their glucose levels. A glucose monitor is used to check the sugar as required

Glycosylated Hemoglobin: HbAlc Blood test that measures the amount of glucose that has been incorporated into the hemoglobin protein of the red blood cell (RBC). Reflects the lifespan of a RBC, so test will reveal the effectiveness of diabetes therapy for the preceding 8-12 weeks. HbA1c levels remain more stable than sugar levels. Not affected by short-term fluctuations in sugar Normal is 4-6% Evaluated periodically (1-2 per year if well controlled, more frequently if not)

Retinopathy Nephropathy Neuropathy Microalbuminuria A1c and relative risk of complications(type 1 diabetes): 20 15 13 Aim for AIc of < 7% 11 9 Relative Risk (%) 7 5 3 1 6 7 8 9 10 11 12 A1c (%) DCCT, Diabetes Control and Complications Trial. 1. Adapted from Skyler JS. Endocrinol Metab Clin North Am. 1996;25:243-254. 2. DCCT. N Eng J Med. 1993;329:977-986. 3. DCCT. Diabetes. 1995;44:968-983.

How to prevent the complications Factors other than blood sugar increase likelihood of complications and should be managed Complications can be delayed/prevented by: • Controlling blood sugars: sticking to diet/exercise programme, taking medication as prescribed • Controlling blood pressure: diet, salt restriction, medication • Controlling cholesterol levels: diet, statin tablets • Stopping smoking • Taking aspirin?

Useful websites • Diabetes Federation of Ireland: • www.diabetes.ie • American Diabetes Association • www.diabetes.org • Irish Nutrition and Dietetic Institute • www.indi.ie • Juvenile Diabetes Research Foundation • www.jdrf.org

• More by User

Diabetes Mellitus. Daozhan Yu [email protected] May 11th, 2005. Diabetes Mellitus. Diabetes – Latin “to flow through”. high urine output (polydipsia) Mellitus- Latin: “honeylike” Glucose in urine (glucosurea). What Are the Symptoms?. Glucosurea

1.34k views • 40 slides

1.79k views • 33 slides

Diabetes Mellitus. NFSC 370 D. Bellis McCafferty. Diabetes Mellitus: A group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. (ADA Website) Approximately 1/3 the people with diabetes are undiagnosed Major cause of:.

1.04k views • 34 slides

DIABETES MELLITUS

DIABETES MELLITUS. Management. IMPORTANT POINTS: IN HISTORY, EXAMINATION, INVESTIGATIONS AND TREATMENT. C ontrol: good / poor? Treatment? C omplications C ardiovascular risk factors. HISTORY: special points. Introduction: ethnic group and age Presenting complaint

922 views • 39 slides

Diabetes Mellitus. A presentation by Meighan O’Connor, POPPF DidacticsOnline.com. Case Presentation. CC: fatigue and abdominal pain

958 views • 16 slides

Diabetes mellitus

Diabetes mellitus. DM – Definition, Prevalence. chronic metabolic disease caused by absolute or relative insufficiency of insulin (or their combination) in the world approximately 270 million diabetic patients raising incidence, mainly DM type 2. Classification DM. DM type 1 DM type 2

888 views • 38 slides

Diabetes Mellitus . Type I Diabetes Mellitus:. Insulin dependent diabetes mellitus. Occurs mostly in childrens . Immune system attacks and destroy beta cells in pancreas that secrete insulin. The pancreas then produces little or no insulin. .

1.13k views • 26 slides

Diabetes Mellitus. Dr. Meg- angela Christi Amores. Diabetes Mellitus. refers to a group of common metabolic disorders that share the phenotype of hyperglycemia Factors: reduced insulin secretion decreased glucose utilization increased glucose production. Classification. Diagnosis.

1.29k views • 22 slides

Diabetes mellitus. Dr Rahmah Kamaludin Family Medicine trainee. Objectives. Define and diagnose Diabetes Mellitus (DM), IFG and IGT What relevant points must be explored in history taking? What investigations are required? Management of DM, IFG and IGT

1.71k views • 105 slides

Diabetes Mellitus. The Ins and Outs. Why is blood sugar control hard for drivers?. Some of the factors related to commercial driving that affect blood glucose control include: Fatigue Lack of sleep Poor diet Missed meals Emotional conditions Stress Concomitant illness.

587 views • 31 slides

Diabetes Mellitus. Andrea Strickland PTA 1010. Diabetes is a metabolic disease. Diabetes is a group of diseases caused by high blood glucose that results from defects in the bodys ability to use or produce insulin More than one in ten American adults have some form of diabetes

844 views • 14 slides

Diabetes Mellitus. Diabetes Mellitus. Learning objectives: The student should have an understanding of the pathogenesis and major histopathological changes seen in diabetes mellitus type 1 and type 2. The student should recognize the major complications of diabetes mellitus.

1.17k views • 46 slides

Diabetes Mellitus. Endocrinology Department, Renji Hospital 陶 弢. Definition Diabetes mellitus is a heterogeneous primary disorder of carbohydrate metabolism with multiple etiologic factors that generally involve absolute or relative insulin deficiency or

1.19k views • 67 slides

Diabetes Mellitus. Type I. Insulin-dependent / Type I DM. require insulin autoimmune attack on β -cells symptoms : when 80% to 90% of β -cells are destroyed. Glucose tolerance test. 75 g of glucose after overnight fast blood glucose every 30 minutes Diabetics: 140 mg/dL (initial)

511 views • 11 slides

DIABETES MELLITUS. ISSUES IN THE LONG TERM CARE SETTING AND ALLIED VENUES. DIABETES MELLITUS. Focus: diabetes in the Medicare population. DIABETES MELLITUS. Definition: a metabolic disorder in which there is deficiency of insulin production or

1.15k views • 46 slides

Diabetes mellitus. by Dr/Amr Gawaly Assistant Lecture Internal Medicine Department Tanta University hospitals. Screening for Diabetes. All adults over 45 years of age. If blood glucose normal and no risk factors present, retest in 3 years

1.3k views • 70 slides

GdT de Enfermedades Cardiovasculares SNaMFAP Enero 2013. DIABETES MELLITUS. Manejo de la hiperglucemia – enfoque centrado en el paciente. Nota: Según la ADA el objetivo glucémico del paciente con DM2 es HbA1c &lt;7,0% (&lt;53 mmol/mol). DM2=diabetes mellitus tipo 2.

1.07k views • 19 slides

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here .

Loading metrics

Open Access

Peer-reviewed

Research Article

Impact of integrative care on cardiovascular disease risk in newly diagnosed type 2 diabetes mellitus patients: A BI-VitalLife Cohort study

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing

Affiliation Bumrungrad International Hospital, Bangkok, Thailand

Roles Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Writing – review & editing

Roles Data curation, Formal analysis, Investigation, Visualization, Writing – review & editing

Roles Project administration, Supervision, Writing – review & editing

Affiliations Bumrungrad International Hospital, Bangkok, Thailand, VitalLife Scientific Wellness Center, Bangkok, Thailand

Roles Conceptualization, Project administration, Supervision, Writing – review & editing

Roles Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing

* E-mail: [email protected] , [email protected] , [email protected] , [email protected] , [email protected]

Affiliations Bumrungrad International Hospital, Bangkok, Thailand, Center of Excellence in Preventive and Integrative Medicine and Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, Department of Infection Biology & Microbiomes, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom

• Tanawat Khunlertkit, 
• Teeradache Viangteeravat, 
• Panupong Wangprapa, 
• Suthee Siriwechdaruk, 
• Jeremy Mark Ford, 
• Krit Pongpirul

• Published: May 29, 2024
• https://doi.org/10.1371/journal.pone.0302438
• Peer Review
• Reader Comments

Introduction

Type 2 diabetes mellitus (T2DM), a chronic metabolic disorder, significantly increases cardiovascular disease (CVD) risk. Integrative care (IC) offers a personalized health management approach, utilizing various interventions to mitigate this risk. However, the impact of IC on CVD risk in newly diagnosed T2Dm patients remains unclear. This study aims to assess the differences in CVD risk development within 120 months following a new diagnosis of T2DM, using real-world data from Bumrungrad International Hospital and Vitallife Scientific Wellness Center.

This study utilized the BI-VitalLife Cohort dataset that contains de-identified demographics, vitals, diagnoses and clinical information, laboratory and radiological data, medications, and treatments of more than 2.8 million patients who visited Bumrungrad International Hospital and/or VitalLife Scientific Wellness Center from June 1, 1999, to May 31, 2022. This study focused on newly diagnosed T2DM patients, defined according to American Diabetes Association criteria. We compared CVD risk between the IC and conventional care (CC) groups using the Kaplan-Meier curve and Cox proportional hazard model, adjusted for age, sex, and laboratory values. Propensity score matching was employed to enhance comparability.

Of the 5,687 patients included, 236 were in the IC group and 5,451 in the CC group. The IC group, characterized by a lower age at T2DM diagnosis, showed favorable hematological and metabolic profiles. The Cox proportional hazard ratios revealed a significantly lower CVD risk in the IC group within 120 months post-T2DM diagnosis compared to the CC group, consistent even after adjusting for confounding factors. Propensity score-matched analysis supported these findings.

Personalized integrative care may offer a significant advantage in reducing CVD risk among newly diagnosed T2DM patients compared to conventional care, even when considering various confounding factors. This study sheds light on the potential of integrative care in informing treatment strategies for T2DM patients at risk of developing CVD.

Citation: Khunlertkit T, Viangteeravat T, Wangprapa P, Siriwechdaruk S, Ford JM, Pongpirul K (2024) Impact of integrative care on cardiovascular disease risk in newly diagnosed type 2 diabetes mellitus patients: A BI-VitalLife Cohort study. PLoS ONE 19(5): e0302438. https://doi.org/10.1371/journal.pone.0302438

Editor: Amirmohammad Khalaji, Tehran University of Medical Sciences, ISLAMIC REPUBLIC OF IRAN

Received: August 17, 2023; Accepted: April 3, 2024; Published: May 29, 2024

Copyright: © 2024 Khunlertkit et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Individuals with type 2 diabetes mellitus (T2DM) are at increased risk of developing cardiovascular diseases (CVD), a leading global cause of death [ 1 , 2 ]. Crucial to mitigating this risk are early detection and lifestyle changes, including diet adaptations [ 3 , 4 ]. Conventional clinical care (CC) for T2DM, typically episodic and illness-focused, follows established guidelines for patient management [ 5 , 6 ]. However, Integrative Care (IC) merges conventional and complementary medicine, offering a more holistic, person-centric approach [ 7 ]. IC emphasizes continuous care and lifestyle modifications such as diet, exercise, and other non-pharmacological interventions to reduce CVD risk [ 8 – 11 ].

The growing popularity of IC lies in its personalized approaches, adapting to individual patient needs. However, the diverse range of therapies and interventions within IC poses unique challenges in clinical study design and the measurement of outcomes, especially in retrospective studies [ 9 – 11 ]. Bumrungrad International Hospital (BIH) and VitalLife Scientific Wellness Center (VSWC) in Bangkok, Thailand, are at the forefront of offering an integrative approach to wellness care.

Utilizing the BI-VitalLife Cohort, a comprehensive dataset from these institutions, this study aims to explore the impact of IC in preventing majore diseases among patients newly diagnosed with T2DM. Specifically, the primary objective of this study is to examine the differences in CVD risk within 120 months after T2DM diagnosis among those receiving IC compared to those undergoing episodic care alone. The choice of this 120-month duration for our study is inspired by the ASCVD 10-year prediction model [ 12 ], a recognized benchmark in cardiovascular research. This timeframe allows us to provide a long-term perspective on the effectiveness of IC in managing CVD risk among T2DM patients, aligning our research with established methodologies in the field. By focusing on this time period, we aim to offer insights into the sustained impacts of IC over a decade, crucial for understanding its long-term benefits in a real-world setting.

This retrospective observational cohort study focused on newly diagnosed T2DM patients, utilizing the BI-VitalLife Cohort dataset ( S1 Dataset ). This dataset includes de-identified demographics, vitals, diagnoses, clinical information, laboratory and radiological data, medications, and treatments for over 2.8 million patients who visited Bumrungrad International Hospital and/or VitalLife Scientific Wellness Center from June 1, 1999, to May 31, 2022. The data were fully anonymized prior to access. The study has been exempted by the Bumrungrad International-Institutional Review Board (BI-IRB) (21-05-294FIEK-B) with no requirement for written informed consent due to the retrospective nature of the study. Also, this study has been carefully conducted in compliance with the Thai Personal Data Protection Act (PDPA) that was announced on May 27, 2019, but has been postponed to enforcement on June 1, 2022.

Determination of incident diabetes mellitus

T2DM was defined in our study as patients who had two consecutive glycemic criteria (GC) that met one of the four laboratory values in the corresponding diabetes ranges outlined by the American Diabetes Association (ADA) guidelines (Normal: HbA1c < 5.7% and Fasting Plasma Glucose (FPG) < = 99 mg/dL and Oral Glucose Tolerance Test (OGTT) < = 139; Prediabetes: HbA1c 5.7–6.4% or FPG 100–125 mg/dL or OGTT 140–199 mg/dL; Diabetes mellitus: HbA1c > = 6.5% or FPG > = 126 mg/dL or OGTT > = 200 mg/dL or Random Plasma Glucose > = 200 mg/dL) [ 13 ]. While the ADA recommends performing the second test the following day, this was not always available in out retrospective cohort dataset. Therefore, we considered all patients with at least two consecutive glycemic tests, one of which must be FPG or HbA1c, who were in the diabetic range within 90 days as eligible for our study. The date of diagnosis of T2DM is the date of the first GC event. Individuals who had received an anti-diabetic agent at the time of diagnosis were excluded as it influences the actual date of diagnosis. Individuals with laboratory values in the GC levels as the first values are also excluded from the studies since the date of onset is indeterminate.

Determination of CVD onset

The date of onset of CVD was defined as the first recorded date of the International Classification of Diseases, Tent Revision (ICD-10) code, ranging from I00 to I99 [ 14 ]. To avoid potential confounding effects, we excluded patients who had received their first CVD diagnosis before their T2DM diagnosis.

Operational definition of integrative care

As IC is an iterative and continuous engagement between the clinician and the client, one of the challenges with this approach is objectively measuring the client’s compliance. However, continuous involvement in IC can make each integrative care visit more personalized and cumulatively effective. Various components of integrated care implemented at VSWC included but not limited to:

• Collaborative Care Planning: Our team of healthcare professionals, including physicians, nurses, and specialists, work together to develop a personalized care plan for each patient. This collaborative approach ensures that all aspects of a patient’s health, including but not limited to dietary habits, exercise habits, current lab values, and/or on-going supplements and medications, are taken into consideration, leading to a comprehensive and holistic care plan.
• Care Coordination and Communication: We prioritize effective communication and coordination among different healthcare providers involved in a patient’s care. This involves sharing information, exchanging insights, and actively involving the patient in decision-making processes. Regular team meetings and electronic health records facilitate seamless coordination and continuity of care.
• Continuity of Care: We emphasize the importance of continuity in healthcare delivery. This involves maintaining a long-term relationship between patients and their healthcare providers, ensuring consistent monitoring, follow-up, and adjustment of the care plan as needed.
• Patient-Centric Approach: Our integrated care model places the patient at the center, recognizing their unique values, preferences, and goals. We engage patients in shared decision-making, empower them to actively participate in their own care, and provide education and support to promote self-management and well-being.

To assess compliance with wellness and disease management, we used the number of visits to VSWC and BIH as a proxy in our study, given the nature of the BI-VitalLife Cohort dataset. We excluded VSWC visits for aesthetic purposes, which were defined by the service provided and/or the medication prescribed or administered. For instance, a VSWC visit for botulinum toxin injection for wrinkle reduction was excluded. Individuals with zero visits to the VSWC were classified as the CC group, while others were classified as the IC group. To explore potential dose-response patterns, we divided the number of VSWC visits into quartiles.

Adjustment variables

In our efforts to minimize potential confounding effects, the study strategically adjusted for key demographic variables, including age and sex. Additionally, we incorporated a range of significant laboratory variables to enhance the accuracy of our comparisons between the CC and IC in terms of their effectiveness on CVD outcomes. These laboratory variables included fasting blood glucose, HbA1c levels, and lipid profile parameters (LDL, HDL, and triglycerides), along with renal function indicators like serum creatinine and estimated glomerular filtration rate (eGFR). These variables were chosen due to their established clinical relevance in the progression of Type 2 Diabetes Mellitus (T2DM) and the associated cardiovascular risks. By adjusting for these specific variables, our analysis aims to provide a more precise and reliable evaluation of the impact of IC compared to CC in the context of CVD risk among T2DM patients.

Statistical analysis

The study employed various statistical techniques to compare the risk of developing CVD between two groups. Descriptive statistics were used to present the characteristics of the individuals in the dataset, while the Kaplan-Meier curve was used to compare CVD risk between the two groups. Cox proportional hazard analysis was performed to compare the risk of developing CVD, adjusting for age, sex, and various laboratory values. Propensity score matching was also used to estimate the effect of one treatment (IC) compared to the other (CC), by taking into account the covariates that predict the likelihood of receiving IC or CC. The propensity score was calculated using logistic regression and a 1:4 or 1:2 nearest neighbor matching algorithm, meaning that each participant in the IC group was matched with four or two participants in the CC group, respectively. Only covariates with a sufficient sample size were included in the analysis.

Characteristics of the participants

The study analyzed data from 5,687 patients (108,415 visits), with 236 patients in the intervention (IC) group and 5,451 in the control (CC) group ( Table 1 ). The mean age at diagnosis of T2DM and CVD were 55.84±13.49 and 61.85±12.18 years old, respectively. The IC group had a significantly lower mean age at diagnosis of T2DM than the CC group (51.00±13.10 vs 56.05±13.47, p<0.001), higher hematocrit (41.73±4.93 vs 40.72±5.45, p = 0.008) and hemoglobin levels (13.94±1.74 vs 13.58±1.95, p = 0.009), lower white blood cells (7.17±2.59 vs 7.94±4.32, p = 0.007) and neutrophil counts (4,240±230 vs 4,970±360, p = 0.002), higher total cholesterol (204.14±55.91 vs 196.39±52.78, p = 0.034), better kidney function (creatinine 0.86±0.90 vs 0.98±0.74, p = 0.019; estimated glomerular filtration rate [eGFR] 100.68±21.69 vs 90.82±25.35, p<0.001) and lower erythrocyte sedimentation rate (ESR 20.39±18.69 vs 35.64±30.55, p<0.001) ( Table 2 ).

• PPT PowerPoint slide
• PNG larger image
• TIFF original image

https://doi.org/10.1371/journal.pone.0302438.t001

https://doi.org/10.1371/journal.pone.0302438.t002

Kaplan-Meier survival analysis: IC vs. CC

The risk of developing CVD within 120 months after being diagnosed with T2DM was significantly lower in the IC group than in the CC group, as demonstrated by Kaplan-Meier survival analysis (p = 3.89x10 -6 ) ( Fig 1 ). Stratification by sex shows statistical significance for both women and men (p = 2.58x10 -3 and 4.51x10 -4 , respectively) ( Fig 2 ). When stratified by age at diagnosis, the risk of developing CVD was significantly lower in the IC group than in the CC group for patients diagnosed with T2DM between the ages of 40 and 60 (p = 3.32x10 -5 ), but not for those diagnosed after the age of 60 (p = 3.10x10 -1 ) ( Fig 3 ).

Kaplan-Meier survival curves depicting the difference in cardiovascular disease (CVD) risk over 120 months post-diagnosis of type 2 diabetes mellitus (T2DM). The curves compare the survival probabilities of patients receiving Integrative Care (IC) versus those receiving Conventional Care (CC), with the number of patients at risk provided at various time intervals. The IC group demonstrates improved survival rates over time compared to the CC group.

https://doi.org/10.1371/journal.pone.0302438.g001

Kaplan-Meier survival curves stratified by sex, comparing the survival probabilities of male and female patients receiving Integrative Care (IC) versus those receiving Conventional Care (CC) over a 120-month period post-Type 2 Diabetes Mellitus (T2DM) diagnosis. The curves indicate a consistently higher survival probability for patients in the IC group across both sexes, with the number of patients at risk displayed at standard time intervals, reflecting the sex-specific influence on the effectiveness of IC in reducing CVD risk.

https://doi.org/10.1371/journal.pone.0302438.g002

Kaplan-Meier survival curves stratified by age, illustrating the survival probabilities of patients receiving Integrative Care (IC) versus those receiving Conventional Care (CC) over a 120-month period post-Type 2 Diabetes Mellitus (T2DM) diagnosis. These curves display the survival outcomes for different age groups within the study population, with a table below indicating the number of patients at risk at specified intervals. The comparison highlights the nuanced impact of IC on CVD risk reduction across various age demographics.

https://doi.org/10.1371/journal.pone.0302438.g003

Cox proportional hazard: IC vs. CC

In assessing the effectiveness of IC compared to CC, our analysis utilized Cox proportional hazard models, as detailed in Table 3 . The hazard ratios (HRs) revealed a statistically significant protective effect of IC against the development of CVD in T2DM patients. Specifically, Model 0, which did not include any adjustments, showed an HR of 0.460, indicating a strong protective effect of IC. This effect persisted across Model 1 to 6, which incorporated adjustments for age at T2DM diagnosis, sex, creatinine, hemoglobin, neutrophils, and cholesterol, with HRs ranging from 0.502 to 0.516. This slight increase in HRs in the adjusted models suggests a moderate dilution effect attributable to the confounding variables.

https://doi.org/10.1371/journal.pone.0302438.t003

Furthermore, age was identified as a significant factor; the risk of developing CVD increased with age, with HRs ranging from 0.022 to 0.025 for each additional year (p<0.001 across Models 1–6). Additionally, creatinine levels also incluenced CVD risk, with an increase of approximately 0.10 to 0.15 in HR for each additional mg/dl of creatinine (p<0.001 in Models 4–6). Notably, in the adjusted models, the differenct in total cholesterol levels between the IC and CC groups was not statistically significant.

Cox proportional hazard: Quartiles of VSWC visits

Our study also explored the ’dose response’ relationship between the frequency of IC visits to VSWC and CVD protection in T2DM patients. This aspect was analyzed by categorizing IC visits into quartiles and examining their impact on CVD risk using Cox proportional hazard models, as detailed in Table 4 .

https://doi.org/10.1371/journal.pone.0302438.t004

The analysis revealed a notable trend: with each increase in the quartile of VSWC visits, indicative of more frequent IC engagement, there was a significantly reduction in CVD risk. Specifically, in Model 0 (unadjusted), for each higher quartile of visits, the HR for developing CVD decreased by 0.175 (HR 0.825, p = 0.003), suggesting a substantial protective effect of more frequent IC visits.

This protective relationship persisted even after adjusting for confounding variables such as age, sex, hemoglobin, neutrophils, and cholesterol in Models 1–6. In these adjusted models, the HRs ranged between 0.854 and 0.859 (p-values raning from 0.016 to 0.020, indicating that the increased frequency of IC visits continued to be significantly associated with a lower risk of developing CVD.

Cox proportional hazard with propensity score matching

To facilitate a more accurate comparison between IC and CC, our analysis employed a fully adjusted model (Model 6) along with propensity score matching. This approach utilized both 1:4 and 1:2 nearest neighbor matching ratios, aiming to balance the distribution of clinical and demographic variables between the two groups. The details of these comparisons, including the variables’ balances before and after propensity score matching, are presented in S1 Table .

Initially, significant disparities were noted in variables such as age at T2DM diagnosis, RBC, WBC, Neutrophil count and percentage, Lymphocyte percentage, estimated glomerular filtration rate (eGFR), and mean corpuscular hemoglobin concentration (MCHC). However, post-propensity score matching, an increase in p-values was observed, indicating a more balanced distribution between IC and CC groups. Interestingly, matching ratios of 1:4 and 1:2 yielded similar results, suggesting that the number of matched controls did not markedly influence the outcomes.

Propensity score matching effectively aligned the groups on observed covariates, thus allowing for a more robust comparison of IC and CC effects. The consistent Cox proportional hazard ratio of 0.512, even after adjustments, underscores the protective effect of IC relative to CC, thereby reinforcing the study’s validity.

Furthermore, while no significant differences in age at CVD diagnosis were initially found between IC and CC groups, propensity score matching based on age at T2DM diagnosis painted a different picture. It revealed that IC conferred a greater protective effect than CC, emphasizing the critical role of age as a confounding factor in our analysis.

This 20-year retrospective analysis provides compelling evidence that IC significantly reduce the risk of CVD development in patients with T2DM. Patients who engaged in IC at both BIH and VSWC demonstrated a markedly lower incidence of CVD compared to those received only CC at BIH. This key finding highlights the effectiveness of IC’s comprehensive, patient-centered approach over the more segmented and disease-specific focus of traditional CC. By integrating lifestyle management, including diet and exercise modifications, as a core component of therapy, IC offers a proactive strategy to mitigate one of the primary health threats faced by individuals with T2DM.

The remainder of the discussion explores the broader context and implications of this finding. While conventional specialists often focus narrowly on their specific roles in patient care, the IC model prioritizes a holistic view of the patient’s health, aligning with findings from landmark studies like the Framingham Heart Study and EGAT regarding the root causes and predictive risks of CVD [ 15 , 16 ]. This approach underlines the importance of patient participation and lifestyle management in preventing CVD among T2DM patients [ 17 ]. Additionally, our study suggests that the success of IC does not require an extensive array of specialized professionals; rather, a small, well-coordinated team can effectively implement personalized care plans. This finding supports the viability of IC in various healthcare settings and underscores its potential in improving long-term health outcomes for T2DM patients.

Notably, the success of IC does not depend on the involvement of specialized professionals alone. A recent meta-analysis revealed that integrated interventions, including an active endocrinologist, led to moderate improvements in HbA1c, blood pressure, and weight management; however, specific CVD outcomes were not addressed [ 18 ]. Moreover, multicomponent integrated care based on the Chronic Care Model (CCM) demonstrated modest improvements in several surrogate parameters, such as HbA1c, blood pressure, and lipid profiles, according to a meta-analysis published in 2018 [ 19 ]. In the context of our study, IC does not necessitate a large team or an array of professional disciplines. Instead, a small team led by a wellness physician can effectively implement IC by tailoring multiple small interventions to meet the unique needs and preferences of each individual, leading to a course of personalized care with a focus on achieving holistic outcomes. By adopting this approach, we anticipate cumulative and meaningful improvements in the overall health of patients. The findings from our study emphasize that IC can be implemented by a well-organized team, combining the expertise of a wellness physician and other healthcare professionals, without the requirement for an extensive specialized setup. This approach ensures individualized care that addresses specific health concerns, ultimately contributing to better long-term health outcomes for patients with T2DM. Nevertheless, further research and clinical trials are warranted to examine specific CVD outcomes in the context of IC to provide a more comprehensive understanding of its impact on cardiovascular health.

While the benefits of personalized continuum and integrative care may vary between wellness centers or personalized regimens, additional evidence from randomized controlled trials (RCTs) is necessary to establish their effectiveness. Despite this, the present study provides significant insights into the adjunctive benefits of IC for patients with chronic conditions. However, designing an RCT with consistent interventions and controls, participant compliance, and measurable outcomes may limit the external generalizability of the results to other settings. In addition to lifestyle management, the VSWC program incorporates preventive approaches based on eight of the nine ‘Hallmarks of Aging’, including telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication [ 18 ]. The selection of specific interventions that correspond to CVD risk reduction among patients with T2DM who have undergone integrative BIH-VSWC care provides promising directions for future validation studies. To further improve our analysis, further studies will incorporate the remaining hallmark of aging, genomic instability [ 19 , 20 ]. These findings will contribute to a better understanding of the potential benefits of personalized and integrative care for patients with chronic conditions.

The success of personalized continuum and integrative care relies on regular patient follow-up, engagement, and compliance. While the longitudinal data from BI-VitalLife is extensive, the dataset lacks objective measurements of patient participation and adherence to the recommended regime, which limits the ability to derive definitive conclusions. Currently, there are no strict policies or guidelines to determine whether a patient should be included in IC, as all IC clients are voluntarily engaged. This may lead to a population bias, where individuals who participate in IC are already more health-conscious than participating in conventional care. Future studies could benefit from incorporating more rigorous methods of assessing patient participation and adherence to the recommended regime. This could include the use of objective measures, such as wearable technology, to monitor patient behavior and engagement. Additionally, efforts could be made to recruit a more diverse patient population, including those who may not typically seek out integrative care services. By addressing these limitations, we can gain a better understanding of the potential benefits and limitations of personalized and integrative care for a broader patient population.

In this study, we used propensity score matching with a 1:4 ratio to match individuals in both groups based on a set of observed covariates, including age, gender, BMI, smoking status, and comorbidities. The choice of a 1:4 ratio was likely appropriate given the sample size and number of covariates. The sample size of 264 individuals was relatively small, and there were several covariates that needed to be accounted for. The 1:4 ratio allowed for a more robust matching process and improved balance between the two groups. However, it is important to note that the use of PSM alone does not completely eliminate the potential for bias. There may still be unobserved covariates that differ between the two groups and can impact the results. Additionally, the use of PSM can potentially lead to a reduction in sample size, as some individuals may not be included in the analysis if they cannot be matched to an individual in the other group. In this study, the authors reported that 82 individuals were excluded from the analysis due to the inability to match them with an individual in the other group. This reduction in sample size may limit the generalizability of the results to a broader population. Overall, the use of propensity score matching with a 1:4 ratio was an appropriate method for this specific study, given the sample size and number of covariates. However, it is important to consider the potential limitations of PSM, including the possibility of unobserved covariates and reduced sample size, when interpreting the results.

The exclusion of pure aesthetic procedures from the definition of wellness care might be a controversial topic. While some aesthetic procedures may not be considered essential to overall health and well-being, they can offer psychological benefits by improving a person’s appearance and self-esteem. However, these procedures may also carry certain risks and complications that could negatively affect a person’s health and well-being. Wellness care, on the other hand, focuses on promoting and maintaining health and well-being in a holistic way, rather than solely addressing cosmetic concerns. It encompasses a range of practices, such as preventive care, lifestyle management, and disease management, that are designed to promote physical and mental well-being. It is important to note that there may be some overlap between aesthetic procedures and wellness care, as some treatment may offer therapeutic benefits in addition to cosmetic benefits. For example, certain facial treatments may improve skin health and reduce inflammation, leading to a healthier overall appearance. Overall, while the exclusion of pure aesthetic procedures from the definition of wellness care may be appropriate given the focus on promoting overall health and well-being, it is important to consider the potential benefits and risks of these procedures. There may be cases where an aesthetic procedure can contribute to a person’s overall well-being and should be considered as part of their wellness care plan. Ultimately, the promotion of physical and mental health and well-being should remain the primary focus of wellness care, but it should also consider individual needs and preferences to provide comprehensive and personalized care.

A study of 5,687 patients over 20 years found that personalized integrative care can lower the risk of developing cardiovascular disease (CVD) within 120 months of a type 2 diabetes diagnosis. Although the results were significant, further research is needed to validate the effectiveness of specific interventions. This study used big data and statistical analysis to provide new insights into the connection between integrative care and CVD, and it could help establish best practices for integrative medicine. Healthcare providers can use this information to make better treatment decisions for patients with T2DM and CVD. Additionally, these techniques could be adapted to identify recommendations for other diseases.

Supporting information

S1 dataset. bumrungrad-vitallife cohort dataset..

https://doi.org/10.1371/journal.pone.0302438.s001

S1 Table. Characteristics of the participants before and after 1:4 and 1:2 propensity score matching.

https://doi.org/10.1371/journal.pone.0302438.s002

Acknowledgments

We are grateful to Prof. Dr. Nimit Taechakraichana, Assoc. Prof. Dr. Suwatchai Pornratanarangsi, and Dr. Palita Lungchukiet for their valuable guidance and support throughout the process.

• View Article
• PubMed/NCBI
• Google Scholar

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

26 templates

6 templates

first day of school

69 templates

environmental science

37 templates

49 templates

12 templates

World Diabetes Day

It seems that you like this template, world diabetes day presentation, free google slides theme, powerpoint template, and canva presentation template.

Diabetes is a serious illness that affects millions of people all around the world, and making proper treatment, care and information accessible to everyone who needs it is an unresolved issue that needs more awareness. For reasons like these, the United Nations decided to establish November 14th as the World Diabetes Day. The symbol of this day is a blue circle, and this template is inspired by it. Use it to speak about what events will be hold or what problems are still to be solved by adding your information and editing the resources we have included. Every little speech counts when it comes to spreading information about dangerous illnesses like this one.

Features of this template

• 100% editable and easy to modify
• 35 different slides to impress your audience
• Contains easy-to-edit graphics such as graphs, maps, tables, timelines and mockups
• Includes 500+ icons and Flaticon’s extension for customizing your slides
• Designed to be used in Google Slides, Canva, and Microsoft PowerPoint
• 16:9 widescreen format suitable for all types of screens
• Includes information about fonts, colors, and credits of the free resources used

How can I use the template?

Am I free to use the templates?

How to attribute?

Combines with:

This template can be combined with this other one to create the perfect presentation:

Attribution required If you are a free user, you must attribute Slidesgo by keeping the slide where the credits appear. How to attribute?

Related posts on our blog.

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access